drugset / Trial / NCT00963703

Treatment of TNFa Naive Patients With Poor Prognosis Rheumatoid Arthritis

NCT00963703

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine how well Rituximab works in early stages of disease and the effects it has on an inflamed joint and blood cells. This will allow the investigators to get a better understanding of how this treatment affects the inflamed joints of rheumatoid arthritis (RA) patients.

Timeline

Start
2007-12
Primary completion
2012-03
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Rituximab Monoclonal antibody 1000 mg Intravenous

Indications